Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain

PURPOSE: The aim of this study was to evaluate the cost-effectiveness of ribociclib compared to palbociclib, both in combination with letrozole, in the first-line treatment of postmenopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Galve-Calvo, Elena, González-Haba, Eva, Gostkorzewicz, Joana, Martínez, Irene, Pérez-Mitru, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241542/
https://www.ncbi.nlm.nih.gov/pubmed/30532569
http://dx.doi.org/10.2147/CEOR.S178934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241542/
https://www.ncbi.nlm.nih.gov/pubmed/30532569
http://dx.doi.org/10.2147/CEOR.S178934

Ejemplares similares